ESR1 and breast carcinoma: With the majority of patients with advanced ER+ breast cancer expected to receive CDK4/6i as part of their treatment, and the high likelihood of the development of resistance to CDK4/6i in a given patient, the post CDK4/6i treated phenotypes represent new biological states for ER+ breast cancer (11).